Document Detail

Bilateral uveitis associated with fluoroquinolone therapy.
MedLine Citation:
PMID:  21981449     Owner:  NLM     Status:  Publisher    
Context: Retrospective case series, database study and literature review. Forty case reports are described. Objective: To report a possible association between fluoroquinolones and uveitis. Materials and Methods: Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization, and Food and Drug Administration were collected on uveitis associated with systemic fluoroquinolone therapy. A literature review was performed using keywords "uveitis", "fluoroquinolones", and each individual fluoroquinolone name. Additional case reports were collected from the practices of six uveitis subspecialists and one neuro-ophthalmologist. Main Outcome Measures: Data garnered from the reports include the type of fluoroquinolone, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of uveitis, concomitant drugs, systemic disease, dechallenge and rechallenge data. Results: A total of 40 case reports of uveitis associated with fluoroquinolones were identified including 12 men, 27 women, and 1 case in which the gender was not specified. The median age was 54 years. Dosage varied between the different fluoroquinolone drugs, with the median dosage within the range recommended in the package insert for each different fluoroquinolone. Median time from beginning of therapy to appearance of the ADR was 13 days (range 0-20 days). Thirteen patients were 60 years or older, and one patient was taking systemic anti-inflammatory steroids. There were five positive dechallenge case reports. Discussion: According to World Health Organization criteria, the relationship between fluoroquinolone therapy and uveitis is "possible". Causality assessments are based on the time relationship of drug administration, uveitis development, and dechallenge data. Conclusions: Clinicians should be aware of a possible bilateral fluoroquinolone-associated uveitis, particularly the finding of iris transillumination and pigment dispersion.
David M Hinkle; Mark S Dacey; Efrem Mandelcorn; Partho Kalyani; John Mauro; James H Bates; Sarkis H Soukasian; Gary N Holland; C Stephen Foster; Frederick T Fraunfelder; Janet L Davis; Frederick W Fraunfelder
Related Documents :
7427049 - Subclavian and axillary vein compression of musculoskeletal origin.
20961729 - Surgical treatment of primary melanoma of the umbilicus with sentinel lymph node biopsy...
3898309 - Infections caused by drechslera species: case report and review of the literature.
9316329 - Hyperbaric oxygen as an adjunctive treatment for descending necrotizing mediastinitis: ...
2000679 - Bilateral emphysematous pyelonephritis.
1246149 - Aortico-left ventricular tunnel. clinical profile, diagnostic features, and surgical co...
20147849 - Free air intraperitoneally during chemotherapy for acute lymphoblastic leukemia: consid...
21179459 - A reliability-generalization study of journal peer reviews: a multilevel meta-analysis ...
7926319 - Developmental prosopagnosia in asperger syndrome: presentation and discussion of an ind...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-8
Journal Detail:
Title:  Cutaneous and ocular toxicology     Volume:  -     ISSN:  1556-9535     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266892     Medline TA:  Cutan Ocul Toxicol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
MERSI, Cambridge Center , Cambridge, NY , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Simplest Method for Creating Micropatterned Nanostructures on PDMS with UV Light.
Next Document:  Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics. Application in Drug Design.